PSMA-targeted T-cell engager enters phase 1 testing in mCRPC ...

Surgeons at Cleveland Clinic completed the first commericial procedure using the Hugo robot-assisted surgery system in the US. The first US commercial surgical case using the Hugo robot-assisted ...

"We've been doing a lot of work at Johns Hopkins using high-dose testosterone therapies to treat patients with metastatic prostate cancer," says Mark C. Markowski, MD, PhD. In this interview, Mark C.

Enzalutamide plus ADT significantly reduced the risk of radiographic progression or death and castration resistance compared to darolutamide plus ADT in mHSPC patients. The MAIC analysis provided a ...

Expert panel developed guidelines for onabotulinumtoxinA use in OAB, emphasizing patient experience and compliance. Recommendations cover patient counseling, pre-procedure urinalysis, antibiotic use, ...

The AUA/CUA/SUFU guide focuses on a combination of symptoms and positive cultures. Uncomplicated urinary tract infection is one of the most common indications for antimicrobial exposure in otherwise ...

Novel therapies are promising but face questions about patient selection and efficacy. Erectile dysfunction is a common concern among aging males. Not only does ED affect quality of life, but it is ...

Experts weigh in on whether the combined technologies could be the future power couple of prostate cancer diagnosis. Prostate-specific membrane antigen (PSMA) and multiparametric magnetic resonance ...

PSA doubling time, defined as the length of time it takes for a PSA to double based on an exponential growth pattern, and PSA velocity, the rate of change of PSA over time, have been identified in ...

Men's Health | Clinical | Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

Studies show moderate alcohol intake has surprising links to prostate disease. Dr. Parsons is professor of urology, division of urologic oncology, department of urology, Moores UCSD Comprehensive ...

VIR-5500 demonstrated promising PSA response in mCRPC patients, with 58% achieving at least a 50% reduction in PSA levels. No dose-limiting toxicities were observed, and treatment-emergent adverse ...